secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001867096-22-000070
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma stockholders elect three Class I directors and ratify KPMG as auditor
--------------------------------------------------------------------------------

- Proposal 1: All three Class I director nominees elected: Bormann (41.5M for), Kong (46.4M for), Schmid (41.5M for).
- Proposal 2: Ratification of KPMG LLP as auditor for FY 2022 passed with 79.0M for, 687K against, 110K abstain.
- Broker non-votes totaled 32.1M shares on director elections.
- Annual meeting held June 8, 2022; 135.5M shares outstanding and entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000070/0001867096-22-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000070/xers-20220608.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer